Bharat Biotech

About Bharat Biotech

Established in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, Bharat Biotech International Limited is a biotechnology firm based in Hyderabad, India, that specializes in the research, development, and production of vaccines and biotherapeutics. The founders launched the company after returning from the US, with Dr. Ella, a research scientist with a Ph.D. from the University of Wisconsin-Madison, envisioning a company driven by intellectual capital to tackle pressing health challenges. Mrs. Ella complemented this scientific focus with her expertise in finance, marketing, and business development, overseeing the company's broad operational aspects. The company was the first to set up operations in Hyderabad's Genome Valley biotechnology park.

Bharat Biotech operates on a multi-faceted business model that includes developing biogenerics, engaging in contract manufacturing, and conducting research for novel, patent-protected products. This strategy allows for revenue generation while pursuing long-term research goals. The company primarily serves public and private markets, supplying vaccines for large-scale immunization programs globally. Its client base includes governments and international health organizations like UNICEF. Revenue is generated through the sale of its diverse product portfolio, which has been delivered to over 125 countries. The firm has built strategic partnerships with global entities such as the Bill & Melinda Gates Foundation, PATH, US National Institutes of Health, and various universities to advance its research and development pipeline.

The company's product portfolio is extensive, featuring over 19 vaccines and four biotherapeutics for diseases like Hepatitis B, Polio, Rabies, Typhoid, and Rotavirus. A significant milestone was the 1998 launch of Revac-B+®, the world's first Hepatitis B vaccine manufactured without cesium chloride. Other key products include Typbar TCV®, the first clinically proven conjugate Typhoid vaccine to receive WHO-Prequalification, and ROTAVAC®, a rotavirus vaccine developed following one of India's largest efficacy trials. During the COVID-19 pandemic, Bharat Biotech developed COVAXIN®, India's first indigenous COVID-19 vaccine, in collaboration with the Indian Council of Medical Research (ICMR). The company has also ventured into biotherapeutics, launching REGEN-D®, a recombinant human epidermal growth factor for treating diabetic foot ulcers and burns. With over 220 patents, Bharat Biotech has established a strong global presence in the fight against infectious diseases.